Psychedelic Therapy in Washington State: Legal Status and Access

Where Washington Currently Stands

Washington state does not yet have a legal pathway for psilocybin therapy in clinical settings. That said, it is one of the most active states in the country when it comes to psychedelic policy reform, and the legislative picture is moving. Understanding the distinction between what is available now versus what is coming matters if you are trying to make informed decisions about your mental health care.

For the Pacific Northwest seeker weighing options, the good news is that meaningful, professionally supported psychedelic therapy is accessible right now through ketamine. And for those with an eye on psilocybin, the legislative groundwork is being laid, though access through a formal program is still several years away.

Ketamine Therapy in Washington State: Available Now

Ketamine is a Schedule III controlled substance under federal law, meaning it has recognized medical uses and can be legally prescribed by licensed clinicians throughout all 50 states. In Washington, and particularly in Seattle, the ketamine therapy infrastructure is among the most developed on the West Coast.

Clinics offering IV infusions, ketamine-assisted psychotherapy, and esketamine (Spravato, the FDA-approved nasal spray for treatment-resistant depression) operate across Seattle, Bellevue, and Tacoma. Seattle psychedelic therapy seekers have access to a range of modalities, from IV infusions at specialized clinics to telehealth-based sublingual protocols, depending on clinical appropriateness.

Esketamine (Spravato) is FDA-cleared specifically for treatment-resistant depression and requires in-person administration at a certified site with a two-hour observation period. IV ketamine infusions are used off-label for depression, anxiety, PTSD, and chronic pain. Both are legitimate, legal options in Washington today. Telehealth prescribing of compounded ketamine has also remained available through extensions of federal flexibility rules, which the DEA and HHS extended through at least December 2026 while permanent regulations are finalized.

If you are considering ketamine therapy in Seattle or elsewhere in Washington, the key factors to evaluate are the qualifications of your prescribing clinician, the integration support offered alongside the medication, and how well the program’s clinical protocol fits your specific situation. A short ketamine infusion with no preparation or integration is a very different experience from a structured, supported program. The difference in outcomes tends to reflect that gap.

Psilocybin Legal Washington 2026: What the Legislature Has Been Doing

Washington’s most recent legislative session produced serious movement on psilocybin access, even if a bill did not ultimately cross the finish line. Senate Bill 5921, the Washington Medical Psilocybin Act, was introduced in late 2025 by Senator Jesse Salomon and passed out of the Senate Health and Long-Term Care Committee in early February 2026 by a vote of 9 to 1. It then moved to the Ways and Means Committee, where it stalled before the session’s formal deadline, effectively postponing the measure for at least another year.

SB 5921 would have established a Department of Health-regulated program allowing licensed clinicians to administer psilocybin to qualifying patients, with the program set to take effect July 1, 2028 if enacted. The bill was modeled in part on New Mexico’s Medical Psilocybin Act, signed into law in April 2025, and was drafted with input from researchers at the University of Washington and advocates involved in Oregon’s psilocybin services rollout.

Separately, two broader adult-use bills, SB 5201 and HB 1433, backed by the grassroots coalition REACH Washington, were also in play during the 2026 session. These proposals would have regulated psilocybin more like a craft wellness product under the state Liquor and Cannabis Board rather than a medical intervention, and would also have allowed personal cultivation and possession of several natural psychedelics. Neither advanced past committee this session.

The underlying dynamic is significant: multiple competing visions for what psilocybin access in Washington should look like reflect genuine, substantive differences about who gets access, under what conditions, and who controls the framework. That debate is not resolved, but Washington is clearly on a trajectory toward some form of legal access. The question is when, and through which model.

For context on how Washington’s approach compares to other states, including Oregon’s operational program and Colorado’s emerging framework, see our post: Is Psychedelic Therapy Legal in the United States?

What Is Not Yet Available in Washington

Psilocybin outside of a licensed medical or research context remains illegal under both state and federal law. Washington does not currently have a decriminalization ordinance at the state level, though some local jurisdictions have deprioritized low-level enforcement. The University of Washington does operate a psilocybin therapy pilot program for first responders and veterans experiencing PTSD, mood disorders, or substance use disorders, which began serving participants in January 2025. That program is not open to the general public.

MDMA-assisted therapy, which had been in late-stage FDA review, did not receive approval. That process remains in flux at the federal level. Washington residents currently have no legal pathway to MDMA therapy, regardless of clinical rationale.

What the Research Actually Shows

The clinical evidence for psilocybin in mental health treatment has continued to grow, even as the legal picture remains complicated. Published research supports its potential for treatment-resistant depression, end-of-life anxiety, PTSD, and nicotine dependence, among other conditions. Limitations in the existing literature are real: many early trials involved small, relatively homogeneous samples and limited long-term follow-up. Washington’s own Department of Health task force reviewed the current studies and reached similar conclusions, noting both promising findings and methodological gaps that warrant more rigorous research before broad public access.

Ketamine’s evidence base is considerably more established. It has been used in clinical settings for decades, its mechanism of action is better understood, and the FDA-approved nasal spray formulation went through the full approval process. For someone in Washington who is struggling with treatment-resistant depression or is actively working through trauma, ketamine represents a legal, clinically supported option today.

What to Do Right Now

If you are a Washington resident exploring psychedelic therapy, you have a few realistic paths worth considering at this moment.

The most accessible and legally clear option is ketamine therapy. Seattle and the greater Puget Sound area have a well-developed clinical infrastructure, including practices that pair medication with structured preparation and integration support. That integration component is worth prioritizing. Ketamine’s therapeutic potential is most fully realized when the experience is held within a framework, not treated as a standalone infusion.

If you are specifically interested in psilocybin and are willing to look at Oregon, legal facilitated sessions are available there through the state’s licensed service center network. Oregon is a few hours from Seattle, and several facilitators serve Pacific Northwest clients. That is a real option for some people, though it requires planning and carries its own considerations around travel, cost, and clinical fit.

Regardless of which path you are exploring, the preparation and integration work matters at least as much as the experience itself. That is where JourneyŌM’s concierge service is designed to help. We work with seekers to assess readiness, identify the right modality, connect with vetted professionals, and support the full arc of the experience, including what happens after. If you are in Washington and trying to navigate what makes sense for your specific situation, a consultation is a good starting point.